(Reuters) - ZURICH, April 25 - Novartis , the Swiss-based drugs group, will buy rights to the anti-smoking vaccine made by Switzerland's Cytos Biotechnology in a deal valued up to 600 million Swiss francs .
Novartis, which has made vaccines a key part of its growth platform, said it purchased global rights to the vaccine, CYT002-NicQb, which could be ready to market in 2011 after late-stage trials in 2008.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment